Effect of empagliflozin when added to insulin in patients with type 2 diabetes and high cardiovascular (CV) risk: results from EMPA-REG OUTCOME

被引：0
|
作者：
Jurisic-Erzen, D. [1 ]
Johansen, O. [2 ]
George, J. [3 ]
Mattheus, M. [3 ]
Zinman, B. [4 ,5 ]
Inzucchi, S. [6 ]
机构：
[1] Univ Hosp Ctr Rijeka, Rijeka, Croatia
[2] Boehringer Ingelheim Norway KS, Asker, Norway
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[4] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[5] Univ Toronto, Div Endocrinol, Toronto, ON, Canada
[6] Yale Univ, Sch Med, Endocrinol Sect, New Haven, CT USA
来源：
DIABETOLOGIA | 2016年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
732
引用
收藏
页码：S349 / S349
页数：1
相关论文
共 50 条
  • [1] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
    Fitchett, David
    Zinman, Bernard
    Wanner, Christoph
    Lachin, John M.
    Hantel, Stefan
    Salsali, Afshin
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Inzucchi, Silvio E.
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    EUROPEAN HEART JOURNAL, 2016, 37 (19) : 1526 - 1534
  • [2] Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®
    Kaku, Kohei
    Lee, Jisoo
    Mattheus, Michaela
    Kaspers, Stefan
    George, Jyothis
    Woerle, Hans-Juergen
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    Strivay, M.
    Vereecken, G.
    Keymeulen, B.
    Lamkanfi, F.
    CIRCULATION JOURNAL, 2017, 81 (02) : 227 - +
  • [3] Effect of empagliflozin on anthropometry and indices of visceral and total adiposity in patients with type 2 diabetes and high cardiovascular risk: EMPA-REG OUTCOME
    Neeland, L. J.
    McGuire, D. K.
    Fernandez, C. S.
    Mattheus, M.
    Woerle, H. -J.
    Johansen, O.
    Fitchett, D.
    DIABETOLOGIA, 2016, 59 : S348 - S348
  • [4] Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME
    Vaduganathan, Muthiah
    Sattar, Naveed
    Fitchett, David H.
    Ofstad, Anne Pernille
    Brueckmann, Martina
    George, Jyothis T.
    Verma, Subodh
    Mattheus, Michaela
    Wanner, Christoph
    Inzucchi, Silvio E.
    Zinman, Bernard
    Butler, Javed
    DIABETES, 2020, 69
  • [5] Empagliflozin Improves Cardiovascular (CV) Outcomes Regardless of Improvement in Cardiac and Vascular Hemodynamic Markers in Type 2 Diabetes Patients at High CV Risk in EMPA-REG OUTCOME
    Chilton, Robert J.
    Gullestad, Lars
    Park, Sung-Ha
    Fitchett, David
    Silvio, E.
    Hehnke, Uwe
    Woerle, Hans Juergen
    Johansen, Odd Erik
    CIRCULATION, 2017, 136
  • [6] Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®
    Bernard Zinman
    Silvio E. Inzucchi
    Christoph Wanner
    Uwe Hehnke
    Jyothis T. George
    Odd Erik Johansen
    David Fitchett
    Diabetologia, 2018, 61 : 1522 - 1527
  • [7] EFFECT OF EMPAGLIFLOZIN ON CARDIOVASCULAR DEATH IN SUBGROUPS BYAGE: RESULTS FROM EMPA-REG OUTCOME
    D'Emden, M.
    Fitchett, D.
    Kis, Giljanovic S.
    Woerle, H.
    Zinman, B.
    Inzucchi, S.
    NEPHROLOGY, 2016, 21 : 58 - 58
  • [8] Effect of Empagliflozin on Cardiovascular Death in Subgroups by Age: Results from EMPA-REG Outcome
    Ridderstrale, Martin
    Toural, Elvira
    Fitchett, David
    Kis, Sanja Giljanovic
    Woerle, Hans J.
    Mattheus, Michaela
    Zinman, Bernard
    Inzucchi, Silvio E.
    DIABETES, 2016, 65 : A289 - A290
  • [9] Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME
    Toural, E.
    Ridderstrale, M.
    Fitchett, D.
    Kis, S. Giljanovic
    Woerle, H. -J.
    Mattheus, M.
    Zinman, B.
    Inzucchi, S. E.
    DIABETOLOGIA, 2016, 59 : S539 - S540
  • [10] Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME
    Ridderstrale, M.
    Fitchett, D.
    Kis, S. Giljanovic
    Woerle, H. J.
    Mattheus, M.
    Zinman, B.
    Inzucchi, S.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1192 - 1192
12345